The influence of aqueous and plasma cytokines in treatment outcomes for diabetic macular oedema

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1128343

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Diabetic macular oedema (DME) is the commonest cause of central visual loss in diabetics and has been linked to increased levels of vascular endothelial growth factor (VEGF) in the eye. DME is treated with anti-VEGF injections, but these need to be repeated, with some patients failing to respond. We plan to see if levels of VEGF and other inflammatory markers will predict treatment response, so those unlikely to respond can be spared futile treatment and receive alternative treatment earlier.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2020

Funding Scheme: Early Career Fellowships

Funding Amount: $189,384.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Ophthalmology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cytokine assays | diabetic retinopathy | inflammation | monoclonal antibody | vascular endothelial growth factor (VEGF)

Related Links